氯胺酮与电休克治疗重性抑郁发作的系统综述与Meta分析
该系统综述与Meta分析纳入5项平行组随机临床试验(氯胺酮组n=141,ECT组n=137),比较成人重性抑郁发作(MDE)患者接受氯胺酮与电休克治疗(ECT)的疗效。总体合并SMD为-0.39(95%CI -0.81至0.02),但在方法学更严格的试验敏感性分析中ECT优于氯胺酮(SMD -0.45,95%CI -0.75至-0.14),且ECT在应答率(RR 1.27,95%CI 1.06-1.53)和缓解率(RR 1.43,95%CI 1.12-1.82)上均优于氯胺酮。
要点
- 在方法学更强的试验中,ECT在改善抑郁评分上优于氯胺酮(SMD -0.45)。
- ECT的临床应答率(RR 1.27)和缓解率(RR 1.43)均显著高于氯胺酮。
- 两组在达到应答/缓解所需治疗次数及认知结局上无显著差异。
核心结论
- 在成人重性抑郁发作患者中,ECT相比氯胺酮可能具有疗效优势,但现有试验数量少、样本量有限且偏倚风险高。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、ScienceDirect和Google Scholar从建库至2022年5月15日的英文平行组随机临床试验,最终纳入5项试验(氯胺酮组n=141,ECT组n=137)。
主要发现
- 总体合并SMD为-0.39(95%CI -0.81至0.02;I2=45%;5项RCT),差异无统计学意义。
- 方法学更强试验的敏感性分析中ECT优于氯胺酮(SMD -0.45;95%CI -0.75至-0.14;I2=6%;2项RCT)。
- ECT在研究定义的应答率(RR 1.27;95%CI 1.06-1.53;I2=0%;3项RCT)和缓解率(RR 1.43;95%CI 1.12-1.82;I2=0%;2项RCT)上优于氯胺酮。
- 两组在达到应答和缓解所需治疗次数及认知结局上无显著差异。
关键数值与推荐
- 疗效结局为治疗后1周(或最近时间点)的抑郁评分、研究定义的应答率和缓解率,以及达到应答/缓解所需治疗次数。
- 安全性结局为报告的不良反应。
临床怎么用
- 对于成人重性抑郁发作,ECT在临床应答和缓解方面可能优于氯胺酮,但需结合患者具体情况和试验局限性个体化选择。
局限性
- 纳入研究数量少(5项),样本量有限,且所有试验均存在高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification. OBJECTIVE: To compare depression rating outcomes with ketamine vs ECT in adults with MDE and to compare response and remission rates, number of sessions to response and remission, and adverse effects. DATA SOURCES: Two investigators independently systematically searched MEDLINE, ScienceDirect, and Google Scholar databases using a combination of relevant Medical Subject Headings terms and free-text keywords from database inception through May 15, 2022, to identify relevant English-language trials. STUDY SELECTION: Parallel-group randomized clinical trials (RCTs). DATA EXTRACTION AND SYNTHESIS: Two investigators independently extracted data and assessed risk of bias. One-week posttreatment outcomes were pooled as standardized mean difference (SMD; Hedges g) for continuous outcomes and risk ratio (RR) for categorical outcomes in random-effects meta-analyses. MAIN OUTCOMES AND MEASURES: Efficacy outcomes were 1-week (or nearest) posttreatment depression ratings, 1-week (or nearest) study-defined response and remission rates, and number of sessions to treatment response and remission. Safety outcomes were reported adverse effects. RESULTS: Five trials (ketamine group: n = 141; ECT group: n = 137) were meta-analyzed. The overall pooled SMD for posttreatment depression ratings was -0.39 (95% CI, -0.81 to 0.02; I2 = 45%; 5 RCTs). For this efficacy outcome, in a sensitivity analysis of methodologically stronger trials, ECT was superior to ketamine (SMD, -0.45; 95% CI, -0.75 to -0.14; I2 = 6%; 2 RCTs). ECT was also superior to ketamine for study-defined response (RR, 1.27; 95% CI, 1.06-1.53; I2 = 0%; 3 RCTs) and remission (RR, 1.43; 95% CI, 1.12-1.82; I2 = 0%; 2 RCTs) rates. No significant differences were noted between groups for number of sessions to response and remission and for cognitive outcomes. Key limitations were small number of studies, limited sample size, and high risk of bias in all trials. CONCLUSION AND RELEVANCE: The findings of this systematic review and meta-analysis suggest an efficacy advantage for ECT over ketamine in adults with MDE. These conclusions are tempered by the small number and size of existing trials.
引用
- Menon V, Varadharajan N, Faheem A, et al. Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2023. PMID: 37043224. doi:10.1001/jamapsychiatry.2023.0562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。